Study Name:
A Randomized, Double-Blind, Four-Arm, Active and Placebo-Controlled Dose-Finding Study to Evaluate the Efficacy, Tolerability, Safety, and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF) (ELEVATE)
Targeted Disease(s):
Pulmonary Fibrosis
Purpose of Study:
The ELEVATE study is evaluating the safety and efficacy of the investigational drug LYT-100 (deupirfenidone) in people living with IPF. LYT-100 has been modified in a way that slows down metabolism of the drug compared to pirfenidone and has demonstrated improved tolerability compared to pirfenidone in previous studies.
Study Dates:
June 1, 2022 - December 31, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
PureTech
Sponsors:
PureTech Health
Contact:
Wassim Fares, MD
Phone: 617-226-4813
Email: clinicaltrials@puretechhealth.com
ClinicalTrails.gov Identifier:
NCT05321420
